Forward P/S Multiple: Profound Medical Corp (PROF)
Profound Medical Corp. (PROF) is scaling the deployment of TULSA-PRO systems by expanding insurance coverage in the US. This chart from the GURU.Markets terminal illustrates market expectations via the projected P/S metric, while 11.60 represents the current level of the metric. Growth is driven by MRI-therapy patents and recurring sales of consumables, which will facilitate global market share capture through B2B supplies to urological centers.
Summary analytical data breakdowns for profoundmedical.com (PROF)
- market price and analyst price targets:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- debt and liquidity data:
Total Debt to Capital Profound Medical Corp.|PROF - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Profound Medical|PROF - Company Aggregate Debts|Debt to Book Capitalization Ratio Profound Medical Corp.|PROF - Company Long-Term Debt|Company Current Liabilities Profound Medical|Quick Ratio profoundmedical.com
- financial results and valuation multiples details:
PROF - Company Net Income|Expected Profit Profound Medical Corp.|PROF - Market Cap to Net Income Ratio|Projected Price to Earnings Profound Medical|PROF - PEG Multiple|EV/EBITDA Multiple Profound Medical Corp.|PROF - Operating income before deduction of amortization|Earnings per share for the last twelve months Profound Medical|PROF - Earnings per one share for the last 12 months|Year-over-year earnings per share growth for the last twelve months profoundmedical.com|PROF - Net earnings per share growth this year|Earnings growth forecast for next year Profound Medical Corp.
- sales and revenue indicators:
Fundamental company analysis:PROF (Profound Medical Corporation)
Profound Medical Corp. maintains its leadership in non-invasive prostate cancer therapy due to the high level of trust urologists place in its MRI systems. GURU.Markets analysts utilize the forward P/S multiple to assess the ratio of market value to projected revenue, accounting for tax incentives, which allows them to determine the business's margin of safety and the risk of overpaying for the issuer's innovative potential.
Who Profound Medical Corp. competes with
Price-to-Projected Revenue Ratio Dexcom DXCM|PEN - Forward Price-to-Revenue Multiple|Novanta Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio Haemonetics Company|INSP: Forward P/S Multiple|Market Cap to Projected Revenue PRCT|CNMD (CONMED) - Forward P/S Multiple|Pulse Biosciences Inc (PLSE) - Market Cap to Expected Sales Ratio|Forward P/S Multiple INMD|Forward Price-to-Revenue Multiple Picard Group PMI|Forward P/S Multiple SRDX (Surmodics, Inc.)|Forward P/S Multiple senseonics.com SENS|NPCE - Price-to-Projected Revenue Ratio|TCMD: Price-to-Projected Revenue Ratio|SNWV (SANUWAVE Health, Inc.) - Forward Price-to-Revenue Multiple|Outset Medical Corp - Forward Price to Sales|ELMD (SmartVest) - Forward P/S Multiple|Market Cap to Future Revenue Ratio lensar.com LNSR|Price-to-Projected Revenue Ratio AVITA Medical (RCEL)|bairdmed.com (BDMD) - Projected Price to Revenue|EDAP TMS - Forward Price-to-Revenue Multiple|Forward P/S Multiple Apyx Medical Corp APYX|IceCure Medical, Ltd. - Forward P/S Multiple|Market Cap to Expected Sales Ratio Pulmonx Corporation LUNG|telabio.com (TELA) - Price-to-Projected Revenue Ratio|Future Price to Revenue CTSO (CytoSorbents Corporation)|Price-to-Projected Revenue Ratio Sensus Healthcare Corp|Forward Price-to-Revenue Multiple Zynex Corp (ZYXI)|Forward P/S Multiple ECOR|RBOT - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio Inspira Technologies IINN|ICU: Market Cap to Projected Revenue|IRIX: Forward Price-to-Revenue Multiple|Intelligent Bio Solutions - Price to Expected Revenue Ratio|beyondair.net (XAIR) - Price-to-Projected Revenue Ratio|Future Price to Revenue PFSA (profusa.com)|Price-to-Projected Revenue Ratio STRATA Skin Sciences Inc.|GCTK: Forward Price to Sales|Price-to-Projected Revenue Ratio NanoVibronix (NAOV)|VERO - Market Cap to Future Revenue Ratio|Forward P/S Multiple NUWE (Nuwellis, Inc.)|AEMD (aethlonmedical.com) - Future Price to Revenue|ASXC - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Avinger Inc.|BSGM (BioSig Technologies, Inc) - Forward Price-to-Revenue Multiple|Cutera Inc (CUTR) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Know Labs, Inc.|Market Cap to Projected Revenue NARI (inarimedical.com)|Forward P/S Multiple NVRO|reshapelifesciences.com - Market Cap to Projected Revenue|Silk Road Medical Inc. - Forward Price-to-Revenue Multiple
